Houthi Strike on Aramco Sends Brent Through $103
Veröffentlicht am 5. Oktober 2026
Artikel lesen
Hallo! Wir sind Nemo.
Nemo, kurz für „Never Miss Out“, ist eine mobile Investment-Plattform, die Ihnen kuratierte, datenbasierte Anlageideen direkt aufs Smartphone liefert. Sie bietet provisionsfreien Handel mit Aktien, ETFs, Krypto und CFDs sowie KI-gestützte Tools, Marktalarme in Echtzeit und thematische Aktiensammlungen, sogenannte Nemes.
App herunterladen
Scannen Sie den QR-Code, um die Nemo App herunterzuladen und noch heute bei Nemo zu investieren
Let’s be honest, the traditional healthcare experience can be a bit of a slog. You wait weeks for an appointment, sit in a drab room flicking through an ancient magazine, only to get five minutes with a doctor who types furiously without making eye contact. It feels ripe for a shake-up, and as with everything else these days, technology is knocking at the door, promising a revolution. This time, it’s called digital therapeutics.
Now, before you roll your eyes and dismiss this as another wellness app fad, I urge you to look a little closer. I’m not talking about an app that simply counts your steps or reminds you to drink water. I’m talking about software that undergoes the same gruelling clinical trials as a new drug, earns clearance from regulators like the FDA, and can only be accessed with a doctor's prescription. This is software as medicine, and it’s a fascinating, if risky, proposition for any investor with a taste for innovation.
The core idea is quite simple. Instead of a pill to manage, say, diabetes or depression, a patient uses a clinically validated application. This isn't just a digital diary. A platform for diabetes might use real-time data from a glucose monitor to give personalised advice on insulin. An app for mental health could deliver cognitive behavioural therapy sessions that adapt to your specific responses.
To me, the real magic is in the scalability. A pharmaceutical company has to worry about manufacturing, supply chains, and distribution. A software company? Once the code is written and approved, it can be delivered to a million patients as easily as it can to one. This completely changes the economics of treatment, and that’s when my investor senses start tingling. It’s the difference between pressing a vinyl record for every listener and just hitting ‘play’ on Spotify.
For years, this all sounded wonderful in theory but fell flat in practice. The reason? No one wanted to pay for it. A brilliant app is useless if insurers refuse to cover the cost. This, I think, has been the single biggest hurdle for the sector. But the tide is finally turning.
Insurance companies, not known for their charitable spirit, are starting to see the light. They’ve realised that a digital intervention for a chronic condition might cost them a fraction of what they’d spend on years of traditional treatments and hospital visits. When a digital therapeutic can deliver similar, or even better, outcomes for less money, the bean counters take notice. This shift from a self-pay model to one covered by insurance is the rocket fuel this industry has been waiting for. It unlocks the entire healthcare market.
The field is already seeing different strategies emerge. You have companies like DarioHealth, which focuses intensely on chronic conditions like hypertension and diabetes, creating a comprehensive system for patients. Then there are giants like Teladoc, which are integrating these digital treatments into their broader telehealth platforms. And you have the consumer-focused players like Hims & Hers, which are bypassing traditional gatekeepers to offer prescriptions and treatments directly to people comfortable with managing their health through an app. It’s a diverse landscape, and you can explore a collection of these companies in the Software as Medicine basket.
Of course, it’s not all smooth sailing. Investing in this space requires a healthy dose of pragmatism. Many of these companies are still burning through cash as they fight for regulatory approval and insurance coverage. The regulatory pathways can be long and unpredictable. Getting doctors, who are often creatures of habit, to prescribe an app instead of a pill is a significant challenge. And for every company that succeeds, several others will likely fall by the wayside. The risks are real, and anyone promising a sure thing is selling snake oil, digital or otherwise. Still, for those with a long-term view, the potential to be in on the ground floor of a fundamental shift in healthcare is undeniably compelling.
Den vollständigen Aktienkorb ansehen:Digital Therapeutics
Dieser Artikel ist Marketingmaterial und stellt keine Anlageberatung dar. Keine der in diesem Artikel enthaltenen Informationen ist als Beratung, Empfehlung, Angebot oder Aufforderung zum Kauf oder Verkauf eines Finanzprodukts zu verstehen, noch handelt es sich um eine Finanz-, Anlage- oder Handelsberatung. Verweise auf bestimmte Finanzprodukte oder Anlagestrategien dienen ausschließlich der Veranschaulichung bzw. Aufklärung und können ohne vorherige Ankündigung geändert werden. Es liegt in der Verantwortung des Anlegers, jede in Betracht gezogene Anlage zu prüfen, die eigene finanzielle Situation zu bewerten und unabhängigen professionellen Rat einzuholen. Die Wertentwicklung in der Vergangenheit ist kein Indikator für zukünftige Ergebnisse. Bitte beachten Sie unsere Risikoaufklärung.
Veröffentlicht am 5. Oktober 2026
Artikel lesen
Veröffentlicht am 4. Oktober 2026
Artikel lesen
Veröffentlicht am 4. Oktober 2026
Artikel lesen
Veröffentlicht am 3. Oktober 2026
Artikel lesen
Veröffentlicht am 3. Oktober 2026
Artikel lesen